{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:51:06Z","timestamp":1791492666102,"version":"4.3.4"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011668","name":"Empire State Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010956","name":"SUNY Upstate Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tips.2026.09.007","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:01:13Z","timestamp":1790121673000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The emerging landscape for next-generation HNSCC treatment"],"prefix":"10.1016","author":[{"given":"Kailey N.","family":"Jackett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghri","family":"Katerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiranya","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghee","family":"Burkitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Saloura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9243-6615","authenticated-orcid":false,"given":"John","family":"Brognard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.09.007_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1665019","article-title":"Global burden of head and neck cancer: epidemiological transitions, inequities, and projections to 2050","volume":"15","author":"Sun","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105207","article-title":"Beyond EGFR inhibition in head and neck squamous cell carcinoma: overcoming resistance mechanisms and novel therapeutic frontiers","volume":"221","author":"Carosi","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tips.2026.09.007_bb0015","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/lary.32064","article-title":"The evolution of multidisciplinary head and neck cancer treatment","volume":"135","author":"Contrera","year":"2025","journal-title":"Laryngoscope"},{"key":"10.1016\/j.tips.2026.09.007_bb0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-025-00886-w","article-title":"Multi-omics in immunotherapy research for HNSCC: present situation and future perspectives","volume":"9","author":"Liu","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0025","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1158\/0008-5472.CAN-23-3594","article-title":"Integrative multiomics analyses identify molecular subtypes of head and neck squamous cell carcinoma with distinct therapeutic vulnerabilities","volume":"84","author":"Diao","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0030","doi-asserted-by":"crossref","first-page":"508","DOI":"10.18632\/oncotarget.28747","article-title":"Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: insights into RTK dependent and independent mechanisms","volume":"16","author":"Shyamsunder","year":"2025","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2026.09.007_bb0035","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41417-025-00902-y","article-title":"Regulation of nucleotide excision repair by wild-type HRAS signaling in head and neck cancer","volume":"32","author":"Hoxhallari","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.tips.2026.09.007_bb0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","article-title":"Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma","volume":"39","author":"Huang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tips.2026.09.007_bb0045","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-25-1042","article-title":"Suppression of AKT activation through LZK inhibition limits tumor growth in esophageal and head and neck cancers","author":"Katerji","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2026.09.007_bb0050","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.22.02786","article-title":"Personalized biomarker-based umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma: KCSG HN 15-16 TRIUMPH trial","volume":"42","author":"Keam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/biom16020325","article-title":"Targeted protein degradation in cancer: PROTACs, new targets, and clinical mechanisms","volume":"16","author":"Faryal","year":"2026","journal-title":"Biomolecules"},{"key":"10.1016\/j.tips.2026.09.007_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102772","article-title":"A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: charting the course of future therapies","volume":"128","author":"Jimenez-Labaig","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tips.2026.09.007_bb0065","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.tips.2026.09.007_bb0070","article-title":"Current landscape of antibody-drug conjugate development in head and neck cancer","volume":"8","author":"Park","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011633","article-title":"Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"13","author":"Ferris","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2026.09.007_bb0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s10238-025-01574-6","article-title":"Tumor infiltration therapy: from FDA approval to next-generation approaches","volume":"25","author":"Shaik","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.tips.2026.09.007_bb0085","article-title":"Advances in neoantigen-based immunotherapy for head and neck squamous cell carcinoma: a comprehensive review","volume":"15","author":"Jiang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0090","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/2159-8290.CD-24-0934","article-title":"PGV001, a multi-peptide personalized neoantigen vaccine platform: Phase I study in patients with solid and hematologic malignancies in the adjuvant setting","volume":"15","author":"Saxena","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2026.09.007_bb0095","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2326-6066.CIR-23-0609","article-title":"Tumor burden dictates the neoantigen features required to generate an effective cancer vaccine","volume":"12","author":"Garzia","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0100","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/jjco\/hyaf069","article-title":"Near-infrared photoimmunotherapy: basics and clinical application","volume":"55","author":"Okada","year":"2025","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3390\/cancers18030350","article-title":"Outcomes of near-infrared photoimmunotherapy for head and neck cancer: a single-center retrospective study","volume":"18","author":"Tahara","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.09.007_bb0110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00428-026-04528-9","article-title":"Epigenetic alterations in head and neck cancer: a brief update","volume":"489","author":"Hellquist","year":"2026","journal-title":"Virchows Arch."},{"key":"10.1016\/j.tips.2026.09.007_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-020-09944-0","article-title":"Epigenetic modulation of immunotherapy and implications in head and neck cancer","volume":"40","author":"Zhou","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.tips.2026.09.007_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118106","article-title":"Recent update on the development of EZH2 inhibitors and degraders for cancer therapy","volume":"299","author":"Tang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2026.09.007_bb0125","article-title":"Unraveling the immune evasion mechanisms in the tumor microenvironment of head and neck squamous cell carcinoma","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.09.007_bb0130","first-page":"1250","article-title":"A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance","volume":"5","author":"Whitehead","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.tips.2026.09.007_bb0135","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1158\/0008-5472.CAN-17-0267","article-title":"Survival of head and neck cancer cells relies upon LZK kinase-mediated stabilization of mutant p53","volume":"77","author":"Edwards","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/PPO.0000000000000616","article-title":"Targeting HRAS in head and neck cancer: lessons from the past and future promise","volume":"28","author":"Desilets","year":"2022","journal-title":"Cancer J."},{"key":"10.1016\/j.tips.2026.09.007_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189552","article-title":"Expanding the therapeutic applications of PARP inhibitors in cancer by targeting receptor tyrosine kinases","volume":"1881","author":"Jafari","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.tips.2026.09.007_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2023.105558","article-title":"Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: a systematic review","volume":"88","author":"Alves","year":"2023","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tips.2026.09.007_bb0155","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.3390\/cancers16173047","article-title":"Advancements in TGF-\u03b2 targeting therapies for head and neck squamous cell carcinoma","volume":"16","author":"Britton","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.09.007_bb0160","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10555-020-09940-4","article-title":"Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?","volume":"40","author":"Riess","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.tips.2026.09.007_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1738440","article-title":"MYC at the tumor-immune interface: mechanisms of immune escape and immunotherapy resistance","volume":"17","author":"Gonzalez-Larreategui","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.09.007_bb0170","first-page":"63","article-title":"Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies","volume":"8","author":"Zhao","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.tips.2026.09.007_bb0175","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2026.09.007_bb0180","doi-asserted-by":"crossref","first-page":"20495","DOI":"10.1021\/acs.jmedchem.4c01946","article-title":"Discovery of SD-436: a potent, highly selective and efficacious STAT3 PROTAC degrader capable of achieving complete and long-lasting tumor regression","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.09.007_bb0185","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/13543776.2024.2400166","article-title":"An updated patent review of BRD4 degraders","volume":"34","author":"Ma","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.tips.2026.09.007_bb0190","article-title":"Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer","author":"Smalley","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.tips.2026.09.007_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101157","article-title":"Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers","volume":"63","author":"Manikandan","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.tips.2026.09.007_bb0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/cimb48010071","article-title":"Role of the super-enhancer component bromodomain protein 4 in the radiation response of human head and neck squamous cell carcinoma cells","volume":"48","author":"Munakata","year":"2026","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.tips.2026.09.007_bb0205","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","article-title":"Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis","volume":"184","author":"Kaczanowska","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tips.2026.09.007_bb0210","series-title":"Study of KT-333 in Participants With Relapsed\/Refractory Lymphoma or Advanced Solid Tumors","author":"US National Library of Medicine","year":"2025"},{"key":"10.1016\/j.tips.2026.09.007_bb0215","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1158\/1078-0432.CCR-25-0206","article-title":"Izalontamab (SI-B001), a novel EGFRxHER3 bispecific antibody in patients with locally advanced or metastatic epithelial tumor: results from first-in-human phase I\/Ib study","volume":"31","author":"Xue","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0220","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug Conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0225","series-title":"A580 Global Phase I Study","author":"Hutchmed","year":"2025"},{"key":"10.1016\/j.tips.2026.09.007_bb0230","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/cancers17030437","article-title":"Tazemetostat, a selective EZH2 inhibitor, in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a phase 1 trial","volume":"17","author":"Oppelt","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.09.007_bb0235","article-title":"EZH2 inhibitor tazemetostat voluntarily withdrawn from market","volume":"132","author":"Lawrence","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.tips.2026.09.007_bb0240","series-title":"Randomized Phase I Trial of Adjuvant Personalized Cancer Vaccine TG4050 in Resected Locally Advanced Head and Neck Squamous Cell Carcinoma","author":"Le Tourneau","year":"2025"},{"key":"10.1016\/j.tips.2026.09.007_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105936","article-title":"Clinical management of common toxicities with inhibitors targeting the PI3K\/AKT\/mTOR pathway in breast cancer","volume":"11","author":"Jhaveri","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.tips.2026.09.007_bb0250","series-title":"Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer or Cholangiocarcinoma (NCT02699606)","article-title":"A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor","author":"Janssen Research & Development, LLC","year":"2025"},{"key":"10.1016\/j.tips.2026.09.007_bb0255","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s10637-023-01408-w","article-title":"The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines","volume":"41","author":"Schnoell","year":"2023","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.tips.2026.09.007_bb0260","series-title":"Berzosertib Clinical Studies in Advanced Solid Tumors and Radiation-Based Combination Regimens","author":"US National Library of Medicine","year":"2026"},{"key":"10.1016\/j.tips.2026.09.007_bb0265","article-title":"A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib","volume":"5","author":"Simoni-Nieves","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tips.2026.09.007_bb0270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","article-title":"Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: implications for counteracting tumor immune evasion","volume":"23","author":"Xia","year":"2025","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.tips.2026.09.007_bb0275","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-21-4425","article-title":"BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGF\u03b2 signaling to durably suppress tumor growth","volume":"83","author":"Boreddy","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0280","first-page":"43","article-title":"Phase 1\/2 study of the next-generation Nectin-4-targeting antibody\u2013drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours","author":"Perez","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0285","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","article-title":"Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"18","author":"Soulieres","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0290","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0295","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.24.00646","article-title":"Phase II trial of enfortumab vedotin in patients with previously treated advanced head and neck cancer","volume":"43","author":"Swiecicki","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0300","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/1078-0432.CCR-25-3930","article-title":"Becotatug vedotin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a multicenter, phase IIa trial","volume":"32","author":"Xue","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0305","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1535-7163.MCT-23-0298","article-title":"An antibody-drug conjugate directed to tissue factor shows preclinical antitumor activity in head and neck cancer as a single agent and in combination with chemoradiotherapy","volume":"23","author":"Bakema","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2026.09.007_bb0310","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0315","first-page":"1370","article-title":"Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and\/or metastatic squamous cell carcinomas: a phase 2 basket trial","volume":"6","author":"Borcoman","year":"2025","journal-title":"Nat. Can."},{"key":"10.1016\/j.tips.2026.09.007_bb0320","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/cancers17101665","article-title":"Petosemtamab, a bispecific antibody targeting epidermal growth factor receptor (EGFR) and leucine-rich G repeat-containing protein-coupled receptor (LGR5) designed for broad clinical applications","volume":"17","author":"Lundberg","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.09.007_bb0325","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.tips.2026.09.007_bb0330","series-title":"An Open-Label, Single-Center Phase II Trial of Cadonilimab (an Anti-PD-1\/CTLA-4 Bispecific Antibody) in Combination with Platinum-based Dual-Drug Neoadjuvant Chemotherapy for Locally Advanced, Resectable Head and Neck Squamous Cell Carcinoma","author":"C.F.W.D.X.P.F.Q.E","year":"2024"},{"key":"10.1016\/j.tips.2026.09.007_bb0335","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2026.09.007_bb0340","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2026.09.007_bb0345","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1038\/onc.2008.19","article-title":"Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members","volume":"27","author":"Wheeler","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2026.09.007_bb0350","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.ado2857","article-title":"Targeting c-MYC and gain-of-function p53 through inhibition or degradation of the kinase LZK suppresses the growth of HNSCC tumors","volume":"18","author":"Funk","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tips.2026.09.007_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108452","article-title":"Discovery of potent and selective PROTACs for the protein kinase LZK for the treatment of head and neck cancer","volume":"301","author":"Katerji","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2026.09.007_bb0360","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1080\/17568919.2024.2389764","article-title":"Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors","volume":"16","author":"Wang","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.tips.2026.09.007_bb0365","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1039\/D5MD00260E","article-title":"Discovery of a potent and selective PROTAC degrader for STAT3","volume":"16","author":"Wang","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.tips.2026.09.007_bb0370","doi-asserted-by":"crossref","first-page":"19871","DOI":"10.1021\/acs.jmedchem.5c01982","article-title":"Recent advances in peptide linkers for antibody-drug conjugates","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2026.09.007_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.149426","article-title":"Antibody-based targeted protein degradation: mechanisms, challenges and future directions","volume":"337","author":"Li","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.tips.2026.09.007_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/cai2.70068","article-title":"Clinical breakthrough in targeted protein degradation: reflections on the approval of ARV-471","volume":"5","author":"Rao","year":"2026","journal-title":"Cancer Innov."},{"key":"10.1016\/j.tips.2026.09.007_bb0385","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2026.09.007_bb0390","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241309461","article-title":"Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy","volume":"17","author":"Izzo","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0395","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.tips.2026.09.007_bb0400","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13402-025-01152-8","article-title":"A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC","volume":"49","author":"Wang","year":"2026","journal-title":"Cell. Oncol. (Dordr)"},{"key":"10.1016\/j.tips.2026.09.007_bb0405","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1080\/14796694.2025.2511470","article-title":"LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC","volume":"21","author":"Machiels","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0410","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2533488","article-title":"Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tips.2026.09.007_bb0415","article-title":"A first-in-class precision antibody conjugate targeting EGFR, mTOR, and PI3K to treat head and neck cancers","author":"Schnermann","year":"2026","journal-title":"Res. Sq."},{"key":"10.1016\/j.tips.2026.09.007_bb0420","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188128","article-title":"Immunotherapeutic strategies in head and neck cancer: challenges and opportunities","volume":"135","author":"Liu","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2026.09.007_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107687","article-title":"Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma","volume":"170","author":"Cheng","year":"2025","journal-title":"Oral Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0430","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","article-title":"FDA approval summary: lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1-based immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2026.102715","article-title":"Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation","volume":"67","author":"Filippini","year":"2026","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0440","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.3390\/cancers16234108","article-title":"HDAC inhibitors can enhance radiosensitivity of head and neck cancer cells through suppressing DNA repair","volume":"16","author":"Antrobus","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.09.007_bb0445","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-018-0696-4","article-title":"A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma","volume":"37","author":"Teknos","year":"2019","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.tips.2026.09.007_bb0450","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","article-title":"Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112823","article-title":"SMYD3 represses tumor-intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck","volume":"42","author":"Nigam","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2026.09.007_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110854","article-title":"Smyd3-mediated immuno-modulation in HPV-negative head and neck squamous cell carcinoma mouse models","volume":"27","author":"Tsai","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.tips.2026.09.007_bb0465","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41598-024-83396-2","article-title":"SMYD3 drives cell cycle and epithelial-mesenchymal transition pathways through dual gene transcriptional repression and activation in HPV-negative head and neck cancer","volume":"15","author":"Murali","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2026.09.007_bb0470","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.3390\/cancers15194685","article-title":"Role of DNA methylation profiles as potential biomarkers and novel therapeutic targets in head and neck cancer","volume":"15","author":"Burkitt","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.09.007_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.837835","article-title":"Rational combinations of targeted therapy and immune checkpoint inhibitors in head and neck cancers","volume":"12","author":"Chai","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0480","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003026","article-title":"Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma","volume":"10","author":"Haddad","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tips.2026.09.007_bb0485","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41388-023-02912-2","article-title":"Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway","volume":"43","author":"Luo","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.tips.2026.09.007_bb0490","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tips.2026.09.007_bb0495","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-024-02136-y","article-title":"Inavolisib: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2026.09.007_bb0500","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-25-0100","article-title":"Phase I clinical trial of the bifunctional EGFR\/TGF-beta fusion protein ficerafusp alfa (BCA101) alone and in combination with pembrolizumab for advanced solid tumors","volume":"31","author":"Hernando-Calvo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2026.09.007_bb0505","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12943-025-02364-0","article-title":"Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tips.2026.09.007_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116845","article-title":"Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: their roles, mechanisms and challenges","volume":"235","author":"Luo","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tips.2026.09.007_bb0515","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/cancers13205206","article-title":"The key differences between human papillomavirus-positive and -negative head and neck cancers: biological and clinical implications","volume":"13","author":"Powell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2026.09.007_bb0520","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/jamaoto.2026.2045","article-title":"Circulating tumor DNA in head and neck cancer: a review from the American Head and Neck Society","volume":"152","author":"Kansara","year":"2026","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.tips.2026.09.007_bb0525","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/cancers15061826","article-title":"Extracellular vesicles as biomarkers in head and neck squamous cell carcinoma: from diagnosis to disease-free survival","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:39:26Z","timestamp":1791491966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726002361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":105,"alternative-id":["S0165614726002361"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.09.007","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging landscape for next-generation HNSCC treatment","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}